Navigation Links
Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
Date:9/17/2007

-MPM Bio IV NVS Strategic Fund L.P. invests $10 million in Radius-

CAMBRIDGE, Mass., Sept. 17 /PRNewswire/ -- Radius Health ("Radius") announced today that it has granted Novartis (NYSE: NVS) an option to obtain an exclusive worldwide license (except Japan) to develop and commercialize all formulations of BA058, Radius' osteoporosis drug candidate. BA058 is a proprietary analog of hPTHrP (human parathyroid hormone-related protein) currently in Phase II development by Radius. In a separate but related agreement, the MPM Bio IV NVS Strategic Fund L.P. has purchased $10 million of Series C preferred stock of Radius.

In the event that Novartis exercises the option to license BA058, Novartis would assume the global clinical development, manufacturing, and marketing of BA058 and all associated costs. Radius would receive payments on the option exercise and on successful completion of certain development, regulatory, and commercial milestones. These payments together could total more than $500 million, part of which will be paid to Ipsen (Euronext: FR0010259150; IPN), from which Radius licensed BA058 in 2005. In addition, Radius would be eligible to receive royalties on product sales and has retained the option to co-commercialize BA058 in the United States. Additional terms were not disclosed.

"It was our stated intention to partner BA058 prior to commencing Phase III development, as this offers the best opportunity to maximize its value potential for Radius while expediting its development for the patients who need it," said C. Richard Lyttle, Ph.D., President and CEO of Radius. "Through this innovative option arrangement, we have put in place an early mechanism to partner BA058 with Novartis, a global leader in the field of osteoporosis."

"This major commitment by the MPM Bio IV NVS Strategic Fund L.P. reflects our belief in the potential of BA058 to address important unmet needs for osteoporosis patients in the near future, and in the attractive commercial potential of Radius," said Ansbert Gadicke, MD, General Partner of MPM Capital and General Partner of the MPM Bio IV NVS Strategic Fund L.P. "We look forward to following the progress of this exciting bone anabolic agent and to its potential late-stage development by Novartis."

About BA058

PTHrP (parathyroid hormone-related protein) is a critical peptide for promoting new bone formation, with a distinct role from PTH (parathyroid hormone), which primarily regulates calcium homeostasis and bone resorption. BA058 is Radius' proprietary analog of hPTHrP currently in Phase II clinical trials for the treatment of osteoporosis in postmenopausal women. BA058 is designed to build bone without inducing hypercalcemia or significant resorption. Radius acquired exclusive worldwide rights (excluding Japan) to develop, manufacture, and distribute BA058 and its analogs from Ipsen in 2005.

About Radius (http://www.radiuspharm.com)

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. Radius has raised $91.5 million in private equity financing since its establishment in 2003 and is based in Cambridge, Massachusetts

Contact:

Nick Harvey

Chief Financial Officer

(617) 551-4704


'/>"/>
SOURCE Radius
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. State to offer $850K in high-tech training grants
2. Grants worth $800,000 help BellBrook Labs develop products
3. Venture-backed firms could become eligible for federal SBIR grants
4. Mithridion wins grants for Alzheimers research
5. NASDAQ grants Merge more time for compliance
6. Morgridge seed grants attract over 220 proposals
7. Medical College researchers win federal grants
8. NSF grants bolster integrative graduate study at UW-Madison
9. Three state businesses receive technology grants
10. SBC Foundation awards technology grants in Wisconsin
11. Visonex plans to expand with state grants, loan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... in Vilnius, Lithuania, announced today that they have entered into a multiyear collaboration ... to provide CRISPR researchers with additional tools for gene editing across all applications. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Wound Market with the addition of its newest module, US Hemostats & Sealants. ... for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used ...
(Date:10/12/2017)... Diego, CA (PRWEB) , ... ... ... (https://www.onramp.bio/ ) has launched Rosalindâ„¢, the first-ever genomics analysis platform specifically ... all bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who ...
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
Breaking Biology Technology:
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):